Showing results (301-310 of 781) with videos related to
Sort By:
Pageof 79
Expert Review of Hematology|February 17, 2011
Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myelomaJacob P Laubach, Robert L Schlossman, Constantine S Mitsiades, et al.Cancer Research|October 16, 2003
Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cellsDharminder Chauhan, Guilan Li, Reshma Shringarpure, et al.Cancer Metastasis Reviews|December 3, 2017
The proteasome and proteasome inhibitors in multiple myelomaSara Gandolfi, Jacob P Laubach, Teru Hideshima, et al.Blood|October 24, 2002
Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieuTeru Hideshima, Masaharu Akiyama, Toshiaki Hayashi, et al.International Journal of Oncology|February 1, 2014
IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cellsHiromasa Hideshima, Yasuhiro Yoshida, Hiroshi Ikeda, et al.Journal of Cellular Biochemistry|June 5, 2007
Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironmentConstantine S Mitsiades, Nicholas S Mitsiades, Paul G Richardson, et al.Biochemical and Biophysical Research Communications|December 3, 2002
The extracellular calcium Ca2+o-sensing receptor is expressed in myeloma cells and modulates cell proliferationToru Yamaguchi, Mika Yamauchi, Toshitsugu Sugimoto, et al.Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|June 8, 2001
Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell MalignanciesSteven P. Treon, Constantine Mitsiades, Nicholas Mitsiades, et al.Current Pharmaceutical Design|September 29, 2012
New insights into the treatment of multiple myeloma with histone deacetylase inhibitorsMichele Cea, Antonia Cagnetta, Marco Gobbi, et al.British Journal of Haematology|October 13, 2015
Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomideDeepika S Das, Arghya Ray, Yan Song, et al.Pageof 79